+357 96 030922
info@marketpublishers.com

U.S. Small Molecule Innovator CDMO Market Size, Share & Trends Analysis Report By Product (Small Molecule API, Small Molecule Drug Product), By Stage Type, By Therapeutic Area, By Customer Type, And Segment Forecasts, 2025 - 2033

https://marketpublishers.com/r/U567F3FFA075EN.html
Date: August 2025
Pages: 120
Price: US$ 5,950.00 (Single User License)
ID: U567F3FFA075EN

Abstracts

U.S. Small Molecule Innovator CDMO Trends

The U.S. small molecule innovator CDMO market size was estimated at USD 15.58 billion in 2024 and is projected to reach USD 26.06 billion by 2033, growing at a CAGR of 6.04% from 2025 to 2033. The growth of the market is due to the rising demand from emerging and mid-sized pharmaceutical companies developing novel chemical entities. These firms often lack in-house manufacturing infrastructure and are increasingly relying on CDMOs for API synthesis, formulation development, and early-phase clinical supply. As innovation in small molecule pipelines continues across oncology, neurology, metabolic disorders, and anti-infectives, CDMOs with strong capabilities in handling complex chemistry, high-potency APIs, and oral solid dosage forms are witnessing increased project volumes. Cost pressures, the need for speed-to-clinic, and regulatory support for accelerated pathways are further fueling outsourcing decisions.

Furthermore, the market is primarily driven by the surge in novel chemical entity (NCE) development, particularly from small and mid-sized pharmaceutical firms. These companies increasingly seek outsourced partners to manage process development, scale-up, and GMP manufacturing as they move from discovery to clinical testing. The complexity of today's small molecule drug candidates, including highly potent APIs (HPAPIs), chiral compounds, and poorly soluble molecules demand specialized technical capabilities that CDMOs are uniquely positioned to provide. Moreover, regulatory flexibility for first-in-human and fast-track pathways is encouraging innovators

+357 96 030922
info@marketpublishers.com

to compress development timelines, further elevating demand for CDMOs with integrated early-phase services.

In addition, the growing preference for domestic manufacturing in response to supply chain vulnerabilities and geopolitical uncertainty is also driving the market growth. Innovator pharmaceutical companies are increasingly shifting away from offshore production, particularly in India and China, due to concerns around quality assurance, long lead times, and regulatory compliance issues. This trend has been further reinforced by government incentives such as the U.S. FDA's support for onshore advanced manufacturing and funding through the BARDA and ASPR programs. As a result, U.S.-based CDMOs with cGMP-compliant facilities, strong quality track records, and proximity to clinical sites are being prioritized for both early-phase and commercial production.

U.S. Small Molecule Innovator CDMO Market Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global U.S. small molecule innovator CDMO market report based on product, stage type, customer type, and therapeutic area.

Product Outlook (Revenue, USD Million, 2021 - 2033)

Small Molecule API

Small Molecule Drug Product

Oral Solid Dose

Semi-Solid Dose

Liquid Dose

Others

Stage Type Outlook (Revenue, USD Million, 2021 - 2033)

Preclinical

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)

Cardiovascular Diseases

Oncology

Respiratory Disorders

Neurology

Metabolic Disorders

Infectious Diseases

Others

This report can be delivered to the clients within 2 Business Days

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

CHAPTER 6. U.S. SMALL MOLECULE INNOVATOR CDMO MARKET: CUSTOMER TYPE ESTIMATES & TREND ANALYSIS

+357 96 030922
info@marketpublishers.com

CHAPTER 7. U.S. SMALL MOLECULE INNOVATOR CDMO MARKET: THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS

CHAPTER 8. COMPETITIVE LANDSCAPE

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: U.S. Small Molecule Innovator CDMO Market Size, Share & Trends Analysis Report By Product (Small Molecule API, Small Molecule Drug Product), By Stage Type, By Therapeutic Area, By Customer Type, And Segment Forecasts, 2025 - 2033

Product link: https://marketpublishers.com/r/U567F3FFA075EN.html

Price: US$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/U567F3FFA075EN.html